1. Home
  2. JKHY vs BIO Comparison

JKHY vs BIO Comparison

Compare JKHY & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jack Henry & Associates Inc.

JKHY

Jack Henry & Associates Inc.

N/A

Current Price

$143.96

Market Cap

12.1B

Sector

Technology

ML Signal

N/A

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

N/A

Current Price

$357.71

Market Cap

10.1B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
JKHY
BIO
Founded
1976
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Laboratory Analytical Instruments
Sector
Technology
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
10.1B
IPO Year
2000
1994

Fundamental Metrics

Financial Performance
Metric
JKHY
BIO
Price
$143.96
$357.71
Analyst Decision
Buy
Hold
Analyst Count
20
3
Target Price
$190.39
★ $328.33
AVG Volume (30 Days)
★ 831.7K
230.5K
Earning Date
11-03-2026
10-29-2026
Dividend Yield
★ 1.70%
N/A
EPS Growth
11.86
★ 142.61
EPS
★ 6.98
N/A
Revenue
$1,536,603,000.00
★ $2,583,200,000.00
Revenue This Year
$5.90
N/A
Revenue Next Year
$6.92
$2.47
P/E Ratio
$21.01
★ N/A
Revenue Growth
★ 7.37
0.65
52 Week Low
$121.04
$236.73
52 Week High
$193.39
$396.23

Technical Indicators

Market Signals
Indicator
JKHY
BIO
Relative Strength Index (RSI) 37.39 48.40
Support Level $132.36 $364.41
Resistance Level $157.59 $392.81
Average True Range (ATR) 4.62 9.33
MACD -1.29 -1.87
Stochastic Oscillator 13.75 33.74

Price Performance

Historical Comparison
JKHY
BIO

About JKHY Jack Henry & Associates Inc.

Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: